Metabolic & Liver Regeneration Program
Regenerative regenerative medicine approach for metabolic disorders, liver disease, and organ regeneration. Restoring metabolic function through targeted cellular medicine.
14+
Years of Clinical Experience
4,850+
Patients Treated Worldwide
UK
UK Corporate Structure
190+
Peer-Reviewed Publications
Organ Regeneration & Metabolic Recovery
Our Metabolic & Liver Regeneration Program targets the growing epidemic of metabolic disease — from diabetes and fatty liver to chronic kidney disease. Using the regenerative and anti-fibrotic properties of Wharton's jelly MSCs, we aim to restore organ function, reduce fibrosis, and improve metabolic control.
Prof. Dr. Erdal Karaöz's research has specifically explored MSC applications in liver regeneration and metabolic disorders. Combined with 14+ years of clinical practice, our GMP-certified protocols and JCI-accredited hospital setting provide the highest standards of care for complex metabolic conditions.
Conditions Treated in This Program
Your Metabolic Recovery Journey
A structured approach to metabolic restoration and organ regeneration
Metabolic Profiling
Comprehensive metabolic and organ function assessment
- Complete metabolic panel (HbA1c, fasting glucose, insulin levels)
- Liver function tests (ALT, AST, GGT, albumin)
- Renal function panel (eGFR, creatinine, BUN)
- Abdominal ultrasound or FibroScan review
- Body composition and metabolic rate analysis
- Current medication review and optimisation
Clinical Assessment in Istanbul
In-person evaluation at Liv Hospital Ulus
- Hepatologist/endocrinologist consultation
- Advanced imaging (CT/MRI if required)
- Liver fibrosis staging confirmation
- Baseline organ function documentation
- Treatment protocol finalisation
- Nutritional status assessment
Regenerative Cell Therapy
Targeted MSC treatment for organ regeneration
- GMP-certified Wharton's jelly MSC preparation
- Intravenous MSC infusion (200–300M cells)
- Hepatic artery infusion for advanced liver disease (when indicated)
- Anti-fibrotic and anti-inflammatory action
- Vital sign monitoring throughout procedure
- Post-infusion metabolic panel
Metabolic Optimisation
Comprehensive lifestyle and nutrition programming
- Personalised metabolic nutrition plan
- Blood sugar management protocol
- Liver-supportive diet and supplementation
- Exercise prescription for metabolic health
- Weight management guidance
- Medication adjustment planning with your physician
Long-Term Monitoring
12-month structured metabolic tracking
- Video consultations at 1, 3, 6, and 12 months
- Repeat metabolic panels and organ function tests
- HbA1c and liver enzyme tracking
- Imaging follow-up when indicated
- Nutrition plan adjustments
- Second treatment cycle assessment
Regenerative Protocol Details
Our metabolic program uses targeted MSC therapy to restore organ function and support recovery from fibrotic damage
Systemic IV MSC Infusion
200–300 million Wharton's jelly MSCs delivered intravenously, providing systemic anti-inflammatory and metabolic regulatory effects. MSCs home to damaged organs and secrete regenerative factors.
Targeted Hepatic Delivery
For advanced liver fibrosis or cirrhosis, MSCs can be delivered directly to the liver via hepatic artery catheterisation, maximising cell concentration at the site of damage.
Anti-Fibrotic Action
MSCs actively support recovery from fibrosis by suppressing hepatic stellate cell activation and promoting the breakdown of excess collagen — addressing the underlying cause of organ damage, not just symptoms.
Metabolic Reprogramming
MSC therapy improves insulin sensitivity, promotes beta-cell regeneration in diabetic patients, and restores hepatocyte function in liver disease — supporting long-term metabolic stability.
Metabolic Support Framework
Our integrated approach addresses the full spectrum of metabolic health
UK-Registered Corporate Structure
StemCell Longevita operates under a UK corporate structure, providing international patients with the governance standards and consumer protections they expect.
- UK-registered company with full corporate transparency
- Contracts governed by English law for international patient protection
- Dedicated UK-based patient coordination and aftercare team
Frequently Asked Questions
Can stem cells help support liver recovery from fibrosis?
Clinical evidence shows MSCs have significant anti-fibrotic properties. They suppress the activation of hepatic stellate cells (the primary drivers of fibrosis) and promote the degradation of excess collagen. Many patients show improvement in FibroScan scores and liver function tests within 3–6 months.
Is this program suitable for Type 1 or Type 2 diabetes?
Our program addresses both types. For Type 2, MSCs improve insulin sensitivity and may help reduce medication dependence. For Type 1, MSCs modulate the autoimmune attack on beta cells and may support residual beta-cell function. Individual assessment determines the optimal protocol.
What about patients with kidney disease?
MSC therapy shows promise for slowing chronic kidney disease progression by reducing renal fibrosis and inflammation. Our program includes comprehensive renal function monitoring and coordination with your nephrologist for medication adjustments.
How does the hepatic artery delivery work?
Hepatic artery infusion is a minimally invasive procedure performed under imaging guidance. A catheter delivers MSCs directly to the liver through the hepatic artery, ensuring maximum cell concentration at the target organ. It is performed at Liv Hospital by experienced interventional radiologists.
Related clinical questions
Where this page sits in the wider picture.